Sign inJoin free

Watch / Global Markets

Microsoft and Meta surge post-earnings as US tariffs hit Rio

31 July 202513:48

Microsoft and Meta surge post-earnings as US tariffs hit Rio

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key Points:

  • US stock market volatility follows Federal Reserve’s interest rate stance and currency strength

  • Microsoft ($MSFT) and Meta ($META) post robust trading results, drawing investor focus

  • President Trump’s tariffs put pressure on Indian exports including autos and pharmaceuticals

  • India’s economic growth may moderate, prompting investment towards local sectors such as banking and manufacturing

Global markets remain on edge as US equities experienced notable declines, driven by renewed strength in the US dollar following signals from Jerome Powell that interest rates will likely stay unchanged for now. Microsoft (NASDAQ: MSFT) and Meta (NASDAQ: META) captured investor attention with strong after-hours trading, Microsoft delivering 18% revenue growth and Azure cloud sales surpassing $75 billion annually. Meta also saw a 10% share jump after third quarter revenue forecasts exceeded expectations, despite projecting a slower growth rate in the coming quarter.

India’s economic outlook is shadowed by escalating trade tensions, with President Trump set to implement a 25% tariff on Indian goods from August 1, and the threat of a 200% tariff on pharmaceuticals. According to McGuffin Siva from India Avenue Investment Management, sectors such as auto ancillary parts, autos, pharmaceuticals, gems and jewellery could face significant headwinds, given that US trade represents around 20% of Indian exports. Siva highlights the complexity of the situation, as exclusions and threats in the pharmaceutical sector lack clarity, with 40% of Indian pharma exports reliant on the US market.

Siva foresees India's GDP growth potentially easing down to 5.5–6% due to external trade pressures. He sees opportunity shifting towards localised consumption, banking and manufacturing sectors, reinforced by recent and anticipated central bank rate cuts, as India pivots focus to its domestic economy.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy